OBI (OBI) News
Follow OBI (OBI) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 7 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Ondine Biomedical Reports H1 2026 Operating Loss Increased To $15.90 Mln
Ondine Biomedical Inc LSE:OBI
NEWS | Sep 30, 2026, 07:48 AM UTC
L
Canada's Ondine Biomedical H1 revenue jumps on new hospital deployments
OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feed
EARNINGS | Sep 30, 2026, 06:14 AM UTC
L
Ondine Biomedical Target Started at 29p by Peel Hunt
Ondine Biomedical Target Started at 29p by Peel Hunt
NEWS | Sep 15, 2026, 09:25 AM UTC
L
Ondine Biomedical Started at Buy by Peel Hunt
Ondine Biomedical Started at Buy by Peel Hunt
NEWS | Sep 15, 2026, 09:25 AM UTC
M
OBI Phase 3 shows 40.5% fewer 30-day surgical site infections
OBI’s LANTERN Phase 3 study met its primary endpoint, reporting a 40.5% reduction in 30-day surgical site infections with nasal photodisinfection added to standard care. The study cites robust Bayesian and frequentist an
EQUITY | Sep 10, 2026, 05:40 PM UTC
M
Phase 3 LANTERN study reduces 30-day SSI risk by 40.5% for OBI
The LANTERN Phase 3 study met its primary endpoint, showing a 40.5% reduction in 30-day surgical site infection risk with nasal photodisinfection plus standard care. Safety was favorable, with only mild, transient advers
EQUITY | Sep 10, 2026, 04:53 PM UTC
M
OBI Phase III trial shows 40.5% fewer 30-day surgical site infections
OBI’s LANTERN Phase III study met its primary endpoint, with a 40.5% reduction in 30-day surgical site infections after adding nasal photodisinfection to standard care. The report says analyses supported the result and t
EQUITY | Sep 10, 2026, 04:42 PM UTC
M
OBI Phase 3 LANTERN trial shows 40.5% reduction in 30-day surgical site infections
Ondine Biomedical’s Phase 3 LANTERN trial reported a 40.5% reduction in 30-day surgical site infections using nasal photodisinfection. The company said the results had strong statistical support, with no significant adve
EQUITY | Sep 10, 2026, 10:01 AM UTC
L
Ondine Biomedical pilots Steriwave nasal photodisinfection in Mexico
Ondine Biomedical says Hospitales Ángeles Health System is piloting Steriwave nasal photodisinfection in two flagship Mexican hospitals.
EQUITY | Sep 07, 2026, 06:01 AM UTC
L
Ondine Biomedical major holdings notification via RNS
Ondine Biomedical Inc. has issued an RNS notification of major holdings using a standard form.
EQUITY | Sep 04, 2026, 06:00 AM UTC
L
Ondine Biomedical RNS flags notification of major holdings
Ondine Biomedical has issued an RNS on a standard form notification of major holdings, covering Pentwater.
EQUITY | Sep 03, 2026, 08:59 AM UTC
M
Ondine Biomedical says Lantern trial meets primary efficacy endpoint
Ondine Biomedical says its Lantern trial met the primary efficacy endpoint.
EQUITY | Sep 01, 2026, 07:21 AM UTC
M
Ondine Biomedical positive topline results in US Phase 3 study
Ondine Biomedical reported positive topline results from a US Phase 3 study.
EQUITY | Sep 01, 2026, 06:01 AM UTC